ArticleCancer2019
The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer.
Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Proton pump inhibitors associated with an increased risk of mortality in elderly: a systematic review and meta-analysis.European journal of clinical pharmacology · 2024Pooled it
- Impact of the Gastric Acid Suppressant Use on the Safety and Effectiveness of EGFR-TKIs: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2022Pooled it
- Concomitant Gastric Acid Suppressants on the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-Analysis.International journal of clinical practice · 2022Pooled it
- Acid-suppressive agents and survival outcomes in patients with cancer: a systematic review and meta-analysis.International journal of clinical oncology · 2021Pooled it
- Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer.European journal of drug metabolism and pharmacokinetics · 2022Trial
- Frequency of Clinically Relevant Drug-Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real-World Data.Basic & clinical pharmacology & toxicology · 2026Observational
- Association between proton pump inhibitor co-medication and treatment switching in dasatinib-treated patients with chronic myeloid leukemia: a German real-world evidence study.Annals of hematology · 2026Article
- Immunological Drug-Drug Interactions in Immune Checkpoint Inhibitor Therapy: Mechanisms, Clinical Evidence, and Artificial Intelligence.Current oncology reports · 2026Review
- Review
- Severe Impact of Omeprazole Timing on pH-Sensitive Dasatinib Absorption: Unveiling Substantial Drug-Drug Interaction.Journal of clinical pharmacology · 2025Article
- Stress pathway outputs are encoded by pH-dependent clustering of kinase components.Nature communications · 2024Article
- Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges?The AAPS journal · 2024Review
- Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans.Leukemia · 2023Article
- Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.Journal of cancer research and clinical oncology · 2023Article
- Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer.JAMA network open · 2023Article
- Precision Oncology in Gastrointestinal Stromal Tumors.Current oncology (Toronto, Ont.) · 2023Review
- Article
- Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure.ESMO open · 2023Review
- Lung cancer, comorbidities, and medication: the infernal trio.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe concomitant use of tyrosine kinase inhibitors (TKIs) and proton pump inhibitors (PPIs) is a significant concern because of potential drug-drug interaction that reduces TKI absorption, thus potentially reducing the effectiveness of TKIs. The objective of this study was to evaluate the prevalence and predictors of concomitant TKI-PPI receipt and its impact on survival and therapy discontinuation in older adults with cancer.
methodsThis retrospective study used linked Surveillance, Epidemiology, and End Results-Medicare data for the years 2007 through 2012. In total, 12,538 patients with lung cancer, renal cell cancer, chronic myelogenous leukemia, liver cancer, or pancreatic cancer were included. The primary exposure variable was concomitant receipt of TKI-PPI, defined as at least 30 days of PPI use in the first 90 days from the start of the TKI (exposure period). The outcomes measured were overall survival and discontinuation of therapy in 90 days and 1 year after the end of the exposure period. Cox proportional-hazards regression with inverse probability of treatment weighting was used to evaluate the association between exposure and outcome.
resultsThe overall prevalence of TKI-PPI receipt was 22.7%. Predictors that were associated with increased use included polypharmacy and prior PPI receipt. TKI-PPI use decreased survival in 90 days (hazard ratio, 1.16; 95% confidence interval, 1.05-1.28) and in 1 year (hazard ratio, 1.10; 95% confidence interval, 1.04-1.18) but was not associated with discontinuation.
conclusionsNearly 1 in 4 older adults with cancer who receive TKIs also receive PPIs concomitantly, and concomitant use is associated with an increased risk of death. Concerted efforts to manage medications are needed to identify and reduce the receipt of PPIs when TKIs are initiated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.